Hidradenitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hidradenitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sonelokimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Fri, 05 Jun 2026 10:52:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sonelokimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin, often in areas like the armpits and groin. The trial will evaluate a treatment called sonelokimab, which is given as a subcutaneous injection, meaning it is injected under the skin. Sonelokimab is a type of medication known as a nanobody, which works by inhibiting proteins called IL-17A and IL-17F that are involved in inflammation. The study will compare the effects of sonelokimab with a placebo, which is a sterile solution that looks like the medication but does not contain any active ingredients.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, which is measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The trial aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa, potentially improving their quality of life by reducing the severity of their symptoms.

]]> Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-of-remibrutinib-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Fri, 29 May 2026 04:02:47 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-of-remibrutinib-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study is being done in adults with hidradenitis suppurativa, a long-lasting skin disease that can cause painful lumps, swelling, and drainage under the skin. The study uses remibrutinib, also known by the code name LOU064, taken as a tablet by mouth. Some participants will receive different doses of remibrutinib, and some will receive placebo. The purpose of the study is to assess the long-term safety of remibrutinib in this condition.

The study is a follow-up, or extension, of earlier research and is designed to continue for a long period. During the study, participants will take the study tablets and return for regular checkups so the study team can watch for any health problems and see how the treatment is being tolerated over time. The study compares the two remibrutinib doses with placebo in a blinded way, which means the treatment given is not revealed to the participants or the study team during the study.

]]> Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/evaluation-of-cit-013-at-two-dose-levels-compared-to-placebo-for-treating-moderate-to-severe-hidradenitis-suppurativa/ Wed, 27 May 2026 04:04:50 +0000 https://clinicaltrials.eu/trial/evaluation-of-cit-013-at-two-dose-levels-compared-to-placebo-for-treating-moderate-to-severe-hidradenitis-suppurativa/ This clinical study focuses on Hidradenitis Suppurativa (HS), a chronic skin condition that causes painful bumps and abscesses in areas where skin rubs together. The study will test a new medication called CIT-013, which will be given through subcutaneous injection (an injection under the skin) to patients with moderate to severe forms of the disease.

The study will compare two different doses of CIT-013 (50 mg and 100 mg) against a placebo to determine how well the medication works in treating the symptoms of Hidradenitis Suppurativa. The purpose is to evaluate if CIT-013 can effectively reduce disease activity in people with this condition.

During the study, participants will receive multiple doses of either CIT-013 or placebo over several weeks. The treatment will be administered as a concentrate that is prepared as a solution for injection. The study will monitor various aspects of the disease, including changes in the number of skin lesions, pain levels, and overall quality of life for the participants.

]]> Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effects-of-remibrutinib-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Mon, 04 May 2026 08:02:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-remibrutinib-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is characterized by painful lumps under the skin, often in areas like the armpits and groin. The study will evaluate the effectiveness and safety of a medication called Remibrutinib, which is taken as a film-coated tablet. Remibrutinib works by inhibiting a specific enzyme in the body, potentially reducing inflammation and the formation of these painful lumps.

Participants in the study will be randomly assigned to receive either Remibrutinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 68 weeks, during which the participants’ response to the treatment will be closely monitored. The main goal is to see if Remibrutinib can reduce the number of abscesses and inflammatory nodules by at least 50% after 16 weeks of treatment.

In addition to Remibrutinib, the study will also involve the use of other treatments like Triamcinolone Acetonide and Salicylic Acid, which are known for their anti-inflammatory properties, as well as systemic antibiotics like Clindamycin Hydrochloride. These treatments will be used to support the main study medication and help manage the symptoms of Hidradenitis Suppurativa. The study aims to provide valuable information on the potential benefits of Remibrutinib for individuals suffering from this challenging condition.

]]> Study on the Effects of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effects-of-sonelokimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Mon, 04 May 2026 07:58:47 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-sonelokimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin, often in areas like the armpits and groin. The study will evaluate a treatment called sonelokimab, which is given as a subcutaneous injection, meaning it is injected under the skin. Sonelokimab is a type of medication known as a nanobody that works by inhibiting proteins called IL-17A and IL-17F, which are involved in inflammation. The trial will compare the effects of sonelokimab with a placebo, which is a sterile solution that looks like the medication but does not contain any active ingredients.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, as measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The study aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa.

]]> Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-povorcitinib-for-patients-with-moderate-to-severe-hidradenitis-suppurativa-2/ Mon, 04 May 2026 07:50:03 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-povorcitinib-for-patients-with-moderate-to-severe-hidradenitis-suppurativa-2/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin. The study is testing a medication called Povorcitinib (also known by its code name INCB054707) to see how effective and safe it is for people with moderate to severe forms of this condition. Participants in the study will receive either the medication or a placebo, which is a substance with no active ingredients, to compare the effects.

The purpose of the study is to evaluate how well Povorcitinib works in reducing the symptoms of Hidradenitis Suppurativa and to monitor any side effects. The study will last for a period of up to 54 weeks, during which participants will take the medication in the form of oral tablets. Throughout the study, participants will have regular check-ups to assess their response to the treatment and any changes in their condition.

Participants will be monitored for improvements in their symptoms, such as a reduction in the number of painful lumps and overall skin condition. The study aims to provide valuable information on the potential benefits of Povorcitinib for individuals suffering from this challenging skin disease.

]]> A study to evaluate the effectiveness and safety of LAD328 in adults with moderate to severe hidradenitis suppurativa https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-lad328-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:09:47 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-lad328-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study focuses on adults living with Hidradenitis Suppurativa, a long-term skin condition that causes painful bumps, inflammation, and potentially deep tunnels or sores under the skin. The research aims to evaluate the efficacy and safety of a new medication called LAD328, which is a human IgG1 monoclonal antibody against interleukin 21. This type of medicine is a lab-made protein designed to target a specific part of the immune system to help control inflammation. The study will compare the effects of this treatment against a placebo consisting of sodium chloride.

Participants in the study will receive their assigned treatment through an intravenous infusion, which means the medicine is delivered directly into the bloodstream through a needle in a vein. During the course of the study, the safety and how well the medication works will be closely monitored. This includes observing how the body reacts to the treatment and checking general health indicators such as heart rhythm and blood tests.

]]> A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-bfb759-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:09:45 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-bfb759-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study focuses on individuals living with Hidradenitis Suppurativa, a long-term skin condition that causes painful lumps under the skin. These lumps, known as abscesses or inflammatory nodules, often appear in areas where skin rubs together, such as the armpits or groin. The purpose of the study is to evaluate the efficacy and safety of a study drug called BFB759.

Participants in this research will be assigned to receive either BFB759 or a placebo through a subcutaneous injection, which is a shot given into the fatty layer of tissue just under the skin. This is a double-blind study, meaning that neither the participants nor the researchers will know which substance is being administered during the trial. The study is randomized, so the assignment of the treatment is decided by chance.

During the course of the study, the effects of the medication will be monitored over time. Researchers will look at changes in the number of skin lumps and track any adverse events, which are unexpected medical problems or side effects that may occur during treatment. The study will observe how the skin responds to the different doses of the medication compared to the placebo.

]]> A study to evaluate the effectiveness of NAV-240 in adults with moderate-to-severe hidradenitis suppurativa https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-nav-240-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:09:39 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-nav-240-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study investigates a treatment for individuals with Hidradenitis Suppurativa, a chronic skin condition that causes painful bumps, abscesses (painful, pus-filled lumps), and draining tunnels (channels under the skin that leak fluid) under the skin. The research aims to determine if the experimental drug NAV-240 is more effective than a placebo in managing this condition.

Participants in this clinical trial will be randomly assigned to receive either NAV-240 or a placebo consisting of sodium chloride. The medication will be administered through an intravenous method, which means it is delivered directly into a vein using a solution for infusion. To ensure the results are reliable, the study is double-blind, meaning neither the participants nor the researchers know which treatment is being given during the course of the study.

]]> A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-ritlecitinib-tosilate-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:09:26 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-ritlecitinib-tosilate-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study focuses on individuals living with Hidradenitis Suppurativa, a chronic skin condition characterized by painful, red lumps under the skin that can form abscesses or tunnels. The purpose of the study is to evaluate the safety and effectiveness of a medication called ritlecitinib, also known as PF-06651600, compared to a placebo.

During the study, participants will be assigned to receive either the active medication or a placebo in a randomized way, meaning the group assignment is decided by chance. The process is double-blind, which means neither the participants nor the researchers know which substance is being administered. The study will last for a total of 16 weeks, during which time the effects of the treatment on the skin and symptoms will be monitored.

]]> A study to evaluate the effectiveness and safety of zasocitinib in patients with moderate to severe hidradenitis suppurativa https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-zasocitinib-in-patients-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:09:19 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-zasocitinib-in-patients-with-moderate-to-severe-hidradenitis-suppurativa/ This study is designed to evaluate the efficacy and safety of zasocitinib in people living with Hidradenitis Suppurativa. Hidradenitis Suppurativa is a long-term skin condition that causes painful lumps, abscesses (pus-filled bumps), and inflammatory nodules (red, swollen lumps under the skin) to form, typically in areas where skin rubs together. The study focuses on individuals experiencing moderate to severe symptoms of this condition.

Participants in this trial will be assigned to receive either the study drug, zasocitinib, which is taken in the form of an oral capsule, or a placebo. This is a double-blind study, meaning that neither the participants nor the researchers will know which treatment is being administered until the study is completed. This method is used to ensure that the results are not influenced by expectations or biases.

During the course of the study, the progress of the condition will be monitored over several weeks. The main goal is to see how well the medication reduces the number of painful lumps and skin lesions compared to the placebo. The study will also track any adverse events, which are unintended medical problems or side effects that may occur during the treatment period.

]]> Efficacy and Safety Evaluation of Tulisokibart in Moderate to Severe Hidradenitis Suppurativa: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial https://clinicaltrials.eu/trial/efficacy-and-safety-evaluation-of-tulisokibart-in-moderate-to-severe-hidradenitis-suppurativa-a-phase-2b-randomized-double-blind-placebo-controlled-trial/ Wed, 29 Apr 2026 15:08:57 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-evaluation-of-tulisokibart-in-moderate-to-severe-hidradenitis-suppurativa-a-phase-2b-randomized-double-blind-placebo-controlled-trial/

This clinical trial is focused on studying hidradenitis suppurativa, a chronic skin condition that causes small, painful lumps to form under the skin. The study will evaluate a treatment called tulisokibart (also known by its code name MK-7240), which is administered as a solution for injection using a pre-filled injector. The trial will compare the effects of tulisokibart with a placebo to determine its effectiveness and safety in treating moderate to severe cases of hidradenitis suppurativa.

The purpose of the study is to assess how well tulisokibart works in reducing the symptoms of hidradenitis suppurativa. Participants in the study will receive either tulisokibart or a placebo and will be monitored over a period of time to see if there is an improvement in their condition. The study will last for several weeks, and participants will have regular check-ups to track their progress and any changes in their symptoms.

Throughout the study, researchers will look at various outcomes, such as the percentage of participants who experience a significant reduction in their symptoms and any changes in their quality of life. The study will also monitor any side effects or adverse events that participants may experience. This research aims to provide valuable information about the potential benefits and risks of using tulisokibart for treating hidradenitis suppurativa.

]]> A Study of Brivekimig Compared to Placebo in Patients with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/a-study-of-brivekimig-compared-to-placebo-in-patients-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:08:13 +0000 https://clinicaltrials.eu/trial/a-study-of-brivekimig-compared-to-placebo-in-patients-with-moderate-to-severe-hidradenitis-suppurativa/ This study is being conducted for people with hidradenitis suppurativa, a long-term skin condition that causes painful lumps, abscesses (collections of pus under the skin), and tunnels that drain fluid under the skin, usually in areas where skin rubs together such as the armpits, groin, and under the breasts. The condition being studied ranges from moderate to severe forms. The treatment being tested in this study is called brivekimig, which is also known by its code name SAR442970. Some people in the study will receive brivekimig while others will receive placebo. The purpose of this study is to evaluate how well different doses of brivekimig work in treating people with moderate to severe hidradenitis suppurativa.

The study will test different amounts of brivekimig to find out which dose works best for treating the symptoms of hidradenitis suppurativa. Participants will receive the study treatment for a period of time, followed by a maintenance period where treatment continues. During the study, doctors will measure how much the skin condition improves by counting the number of abscesses and inflammatory nodules (swollen, painful bumps), as well as the number of draining tunnels (channels under the skin that leak fluid). They will also assess how the condition affects pain levels and quality of life. The study is designed so that neither the participants nor the doctors know who is receiving brivekimig and who is receiving placebo until the study is completed.

People taking part in this study must have been diagnosed with moderate to severe hidradenitis suppurativa for at least six months and must have lesions in at least two different body areas. They should have tried treatment with oral antibiotics that either did not work well enough, caused problems, or cannot be used for medical reasons. Participants may have never used biologic medications before, or they may have previous experience with them. Throughout the study, doctors will monitor participants for any side effects and will measure the levels of brivekimig in the blood to understand how the medication works in the body.

]]> A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/a-study-of-lad191-compared-to-placebo-and-adalimumab-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:07:49 +0000 https://clinicaltrials.eu/trial/a-study-of-lad191-compared-to-placebo-and-adalimumab-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study is looking at hidradenitis suppurativa, a long-term skin condition that causes painful lumps and abscesses to form under the skin, usually in areas where skin rubs together such as the armpits, groin, buttocks, and under the breasts. The study will test a new medication called LAD191, which is also known by the code name ISB 880. This medication is given as an injection under the skin. Some participants will receive LAD191, some will receive placebo, some will receive sodium chloride solution, and some will receive adalimumab, which is an approved medication already used to treat this condition. The purpose of the study is to see how well different doses of LAD191 work in treating moderate-to-severe hidradenitis suppurativa and to check how safe it is for patients to use.

The study is designed in multiple stages and will compare different treatment groups to understand which approach works best. Participants will receive their assigned treatment through injections under the skin over a period of time. Throughout the study, doctors will count and examine the skin lesions to see if they improve with treatment. They will look specifically at whether the number of abscesses and inflamed bumps decreases by at least half, which is one way to measure if the treatment is working. The study will also monitor participants for any side effects or unwanted reactions to the medication.

During the study, participants will need to continue using over-the-counter antiseptic products on their skin lesions regularly, as they should have been doing before joining the study. The study will track various safety measures including blood tests, heart activity recordings, vital signs like blood pressure and heart rate, and any problems or discomfort at the injection sites. Doctors will carefully watch for any adverse events, serious health problems, or reasons why someone might need to stop treatment early. The study requires that participants have tried antibiotic treatment before without success or were unable to tolerate it, and they must have lesions in at least two different body areas.

]]> Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials https://clinicaltrials.eu/trial/long-term-safety-study-of-oral-povorcitinib-in-patients-with-hidradenitis-suppurativa-prurigo-nodularis-or-vitiligo-who-previously-participated-in-clinical-trials/ Wed, 29 Apr 2026 15:07:07 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-oral-povorcitinib-in-patients-with-hidradenitis-suppurativa-prurigo-nodularis-or-vitiligo-who-previously-participated-in-clinical-trials/ This study focuses on three skin conditions: Hidradenitis Suppurativa (a painful condition causing lumps under the skin), Prurigo Nodularis (a condition causing intensely itchy bumps on the skin), and Vitiligo (a condition where patches of skin lose their color). The study uses Povorcitinib (also known as INCB054707), which is given as tablets that are taken by mouth.

The purpose of this research is to evaluate the long-term safety of Povorcitinib in people who have previously participated in other studies of this medication. The study will continue for up to 36 months, during which participants will continue taking the medication and have their condition monitored.

This is a follow-up study specifically designed for individuals who have already completed treatment with Povorcitinib in previous research studies and have shown improvement in their condition. Throughout the study, doctors will monitor how well the medication continues to work and check for any side effects that might occur with long-term use.

]]> Study of Tibulizumab to Treat Adults with Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-of-tibulizumab-to-treat-adults-with-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:07:01 +0000 https://clinicaltrials.eu/trial/study-of-tibulizumab-to-treat-adults-with-hidradenitis-suppurativa/ This clinical trial focuses on studying hidradenitis suppurativa, a chronic skin condition that causes painful bumps and abscesses in areas where skin rubs together. The study will test a medication called tibulizumab, which will be given as a solution for injection under the skin, compared to a placebo. The purpose is to evaluate how well tibulizumab works in treating the lesions associated with hidradenitis suppurativa.

The study consists of two parts: first, participants will be randomly assigned to receive either tibulizumab or placebo. After this initial period, all participants will have the opportunity to receive tibulizumab in what is called an open-label extension period. The total treatment duration for each participant will be 28 weeks.

During the study, researchers will monitor changes in the number of abscesses and inflammatory nodules (painful bumps under the skin). They will also track improvements in participants’ quality of life, their assessment of the condition’s severity, and any skin pain they experience. Throughout the study, participants’ health will be closely monitored to ensure their safety and to observe how well they tolerate the treatment.

]]> Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-sonelokimab-injections-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:06:43 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-sonelokimab-injections-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ This study focuses on people with moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful bumps and abscesses in areas where skin rubs together. The study will test a medication called sonelokimab (also known as M1095), which is given as an injection under the skin (subcutaneous injection). This medication works by blocking specific proteins in the body called IL-17A and IL-17F that are involved in inflammation.

The purpose of this study is to evaluate how safe and well-tolerated sonelokimab is when used for an extended period in people with hidradenitis suppurativa. This is an extension study, which means that participants who completed previous studies with this medication may continue their treatment to gather long-term information about the medication’s effects.

During the study, participants will receive regular doses of sonelokimab through subcutaneous injections. The treatment period will last approximately 100 weeks, during which participants will have regular check-ups to monitor their health and any side effects that may occur. The maximum daily dose that participants may receive is 120 mg/ml, with a total maximum dose of 3120 mg/ml over the course of the study.

]]> Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa https://clinicaltrials.eu/trial/study-to-measure-bimekizumab-concentration-in-breast-milk-of-breastfeeding-mothers-with-psoriasis-psoriatic-arthritis-axial-spondyloarthritis-or-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:06:37 +0000 https://clinicaltrials.eu/trial/study-to-measure-bimekizumab-concentration-in-breast-milk-of-breastfeeding-mothers-with-psoriasis-psoriatic-arthritis-axial-spondyloarthritis-or-hidradenitis-suppurativa/ This study will investigate how much bimekizumab passes into breast milk in mothers who are being treated with this medication. The study includes women with several chronic inflammatory conditions including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and plaque psoriasis. Bimekizumab is given as an injection under the skin using either pre-filled syringes or pre-filled pens.

The study will collect breast milk samples from mothers who are already receiving bimekizumab treatment as prescribed by their doctor. Samples will be taken over a period of two weeks, with additional samples collected depending on how often the participant receives their medication. The main purpose is to measure the amount of medication that passes into breast milk.

Participants must be at least 18 years old, currently breastfeeding, and have been receiving bimekizumab treatment for at least 12 weeks after giving birth. The study will monitor both mothers and infants for any side effects throughout the study period. The medication dose and schedule will continue as previously prescribed by the participant’s doctor.

]]> Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa https://clinicaltrials.eu/trial/study-of-ruxolitinib-cream-applied-to-the-skin-for-people-with-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:06:30 +0000 https://clinicaltrials.eu/trial/study-of-ruxolitinib-cream-applied-to-the-skin-for-people-with-hidradenitis-suppurativa/ This study focuses on people with Hidradenitis Suppurativa, a chronic skin condition that causes painful bumps to form under the skin, typically in areas where skin rubs together. The research evaluates a medication called ruxolitinib cream, which is applied to the skin twice daily. The cream contains 1.5% of the active ingredient and will be compared to a vehicle cream (a cream without the active medication).

The purpose of this research is to determine how well ruxolitinib cream works in treating mild to moderate Hidradenitis Suppurativa. The study will include people who have had this condition for at least 6 months and have bumps in at least two different body areas. During the study, participants will either use the ruxolitinib cream or the vehicle cream on affected areas of their skin.

The main study period lasts 16 weeks, after which some participants may continue treatment in an extended phase. Throughout the study, participants will need to avoid using certain skin treatments, including antibiotics and antiseptic washes, on the affected areas. Regular check-ups will be conducted to monitor the condition’s response to treatment and ensure participant safety.

]]> Study of ruxolitinib cream for treating hidradenitis suppurativa in adult patients https://clinicaltrials.eu/trial/study-of-ruxolitinib-cream-for-treating-hidradenitis-suppurativa-in-adult-patients/ Wed, 29 Apr 2026 15:06:30 +0000 https://clinicaltrials.eu/trial/study-of-ruxolitinib-cream-for-treating-hidradenitis-suppurativa-in-adult-patients/ This clinical trial studies the effectiveness of ruxolitinib cream in people with Hidradenitis Suppurativa, a chronic skin condition that causes painful bumps under the skin, typically in areas where skin rubs together. The study tests a cream containing ruxolitinib (also known as INCB018424 or Opzelura) compared to a cream without active ingredients (vehicle cream).

The purpose of this research is to determine how well ruxolitinib cream works when applied to the skin twice daily in treating Hidradenitis Suppurativa. The cream is being tested in people who have mild to moderate forms of the condition affecting at least two different body areas, such as the underarms or groin regions.

The study is organized in a way where some participants will receive the ruxolitinib cream while others will receive the vehicle cream. During the study, participants will not be allowed to use certain other treatments for their condition, such as antibiotics or antiseptic washes. The main treatment period lasts for 16 weeks, after which the effectiveness of the treatment will be evaluated based on the reduction in the number of affected areas.

]]> Study of Bimekizumab for Children and Adolescents with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-of-bimekizumab-for-children-and-adolescents-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:06:06 +0000 https://clinicaltrials.eu/trial/study-of-bimekizumab-for-children-and-adolescents-with-moderate-to-severe-hidradenitis-suppurativa/ This study is evaluating bimekizumab, which is administered by injection under the skin (subcutaneous administration), in children and adolescents who have reached puberty and have moderate to severe hidradenitis suppurativa. Hidradenitis suppurativa is a chronic skin condition that causes painful, swollen lumps to form under the skin, typically in areas where skin rubs together, such as the armpits, groin, and under the breasts. These lumps can break open, releasing fluid and potentially becoming infected.

The purpose of this study is to learn how bimekizumab works in the body (its pharmacokinetics) and assess its safety in young patients with this skin condition. Participants will receive the study medication over a treatment period, during which researchers will monitor how the drug moves through the body and collect information about any side effects that occur.

Throughout the study, researchers will measure the concentration of bimekizumab in participants’ blood, track any adverse events, monitor vital signs including blood pressure and pulse, and perform laboratory tests to assess the overall safety of the treatment. They will also check for the development of antibodies against the medication, which can sometimes occur when receiving biological treatments.

]]> Study on Fecal Microbiota Transplantation and Amoxicillin-Clavulanic Acid for Patients with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-fecal-microbiota-transplantation-and-amoxicillin-clavulanic-acid-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:06:04 +0000 https://clinicaltrials.eu/trial/study-on-fecal-microbiota-transplantation-and-amoxicillin-clavulanic-acid-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin. The study will explore a treatment involving a combination of antibiotics and a procedure known as Fecal Microbiota Transplantation (FMT). The antibiotics used in this study are amoxicillin-clavulanic acid, which are commonly used to treat bacterial infections. FMT involves transferring stool from a healthy donor to the patient to help restore a healthy balance of bacteria in the gut.

The purpose of the study is to evaluate how effective this treatment is in reducing the activity of the disease. Participants will first receive the antibiotic treatment, followed by the FMT. The study will monitor changes in the condition over a period of 12 weeks after the FMT. The goal is to see if there is an improvement in the number of painful lumps and other symptoms associated with the disease.

Throughout the study, participants will be assessed for improvements in their condition, including a reduction in the number of lumps and an improvement in their quality of life. The study will also track any side effects that may occur. By the end of the study, researchers hope to determine if this treatment approach can provide significant relief for those suffering from moderate to severe Hidradenitis Suppurativa.

]]> Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-remibrutinib-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:04:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-remibrutinib-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying the effects of a medication called remibrutinib on a skin condition known as hidradenitis suppurativa. Hidradenitis suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where the skin rubs together. The study will compare the effectiveness of remibrutinib to a placebo, which is a substance with no active medication, to see if remibrutinib can help reduce the symptoms of this condition.

The purpose of the study is to assess how well remibrutinib works in reducing the number of painful lumps and abscesses in patients with moderate to severe hidradenitis suppurativa. Participants in the study will receive either remibrutinib or a placebo over a period of 68 weeks. The study will also involve the use of other medications, such as clindamycin hydrochloride, a type of antibiotic, and triamcinolone acetonide, a medication used to reduce inflammation. These medications will be administered to help manage the symptoms of the disease.

Throughout the study, participants will be monitored to evaluate the safety and tolerability of remibrutinib. The study aims to determine if remibrutinib can achieve a significant reduction in the symptoms of hidradenitis suppurativa, such as a decrease in the number of abscesses and inflammatory nodules. The results will help to understand if remibrutinib is a viable treatment option for individuals suffering from this challenging skin condition.

]]> Study on Botulinum Toxin Type A for Treating Hidradenitis Suppurativa in Patients: A Comparison of Different Drug Combinations https://clinicaltrials.eu/trial/study-on-botulinum-toxin-type-a-for-treating-hidradenitis-suppurativa-in-patients-a-comparison-of-different-drug-combinations/ Wed, 29 Apr 2026 15:03:24 +0000 https://clinicaltrials.eu/trial/study-on-botulinum-toxin-type-a-for-treating-hidradenitis-suppurativa-in-patients-a-comparison-of-different-drug-combinations/ This clinical trial is focused on studying the effects of a treatment for Hidradenitis Suppurativa, a chronic skin condition that causes small, painful lumps under the skin. The treatment being tested is Botox, which is a form of botulinum toxin type A. Botox is commonly known for its use in cosmetic procedures, but it is also used in various medical treatments. In this study, Botox will be compared to a placebo to evaluate its effectiveness in reducing the symptoms of Hidradenitis Suppurativa.

The purpose of the study is to assess how well Botox can reduce the activity of Hidradenitis Suppurativa over a period of six months. Participants will receive injections of either Botox or a placebo in affected areas of their skin. The study will monitor changes in the severity of the condition using a scoring system called the IHS4 score, which helps measure the treatment’s effect. The study will also look at other factors, such as the number of painful lumps, patient satisfaction, and overall quality of life improvements.

Participants in the study will be followed for up to 12 months, with regular check-ups to monitor their progress. The study aims to provide valuable information on whether Botox can be an effective treatment option for people suffering from Hidradenitis Suppurativa, potentially offering relief from the symptoms of this challenging condition.

]]> Study on the Effectiveness of IC0624 for Patients with Mild to Moderate Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ic0624-for-patients-with-mild-to-moderate-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:03:20 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ic0624-for-patients-with-mild-to-moderate-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa (HS), which is characterized by painful lumps under the skin, often in areas like the armpits, groin, and buttocks. The study is testing a treatment called IC0624, which is being evaluated as a first-line therapy for people with mild to moderate forms of this condition. The treatment is administered in the form of gastro-resistant tablets, which means they are designed to pass through the stomach without dissolving until they reach the intestines.

The purpose of the study is to assess the effectiveness of taking IC0624 over a period of six weeks. Participants will be randomly assigned to receive either the active treatment or a placebo, which looks like the treatment but does not contain the active substance. The study is conducted in a double-blind manner, meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their symptoms. The main goal is to see if the treatment can reduce the number of lumps and improve the overall condition of the skin. Additional assessments will include checking for any side effects and evaluating the participants’ quality of life during the treatment period. The study aims to provide valuable information on the potential benefits of IC0624 for people living with Hidradenitis Suppurativa.

]]> Study on the Effectiveness and Safety of Brensocatib for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-brensocatib-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:03:20 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-brensocatib-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying the effects of a medication called Brensocatib on adults with a skin condition known as Hidradenitis Suppurativa. Hidradenitis Suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The study aims to evaluate how effective and safe Brensocatib is in treating this condition.

Participants in the study will receive either Brensocatib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for up to 52 weeks, during which participants will take the medication in the form of a film-coated tablet. The main goal is to observe changes in the number of painful lumps and abscesses over time, particularly at the 16-week mark.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving Brensocatib and who is receiving the placebo. This helps ensure that the results are unbiased. The trial will take place at multiple centers, allowing for a diverse group of participants to be involved. The findings from this study could provide valuable insights into the treatment of Hidradenitis Suppurativa with Brensocatib.

]]> Study on the Safety of INF904 for Patients with Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-safety-of-inf904-for-patients-with-moderate-to-severe-chronic-spontaneous-urticaria-or-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:03:12 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-inf904-for-patients-with-moderate-to-severe-chronic-spontaneous-urticaria-or-hidradenitis-suppurativa/ This clinical trial is focused on studying two conditions: Chronic Spontaneous Urticaria (CSU) and Hidradenitis Suppurativa (HS). These are conditions where the body experiences persistent hives or painful lumps under the skin, respectively. The study will use a treatment called INF904, which is taken as a soft capsule by mouth. INF904 is a type of medication known as a C5aR1 inhibitor, which is designed to help manage these conditions by targeting specific pathways in the body that contribute to inflammation and symptoms.

The purpose of the study is to determine the safety of INF904 when taken in multiple doses by people with moderate to severe CSU or HS. Participants will take the medication over a period of time, and researchers will monitor them to see how their bodies respond to the treatment. This includes looking at how the medication is absorbed and processed in the body, which is known as pharmacokinetics. The study will also track any side effects or adverse events that occur during the trial.

Participants in the study will be asked to take the medication as directed and attend regular check-ups with the research team. These visits will help ensure that the treatment is working as intended and that any potential side effects are managed. The study aims to provide valuable information on the safety and effectiveness of INF904 for people living with CSU or HS, potentially leading to better treatment options in the future.

]]> Study on Clindamycin and Rifampicin for Treating Infections in Patients with Obesity, Fracture-Related Infections, Hidradenitis Suppurativa, or Prosthetic Joint Infections https://clinicaltrials.eu/trial/study-on-clindamycin-and-rifampicin-for-treating-infections-in-patients-with-obesity-fracture-related-infections-hidradenitis-suppurativa-or-prosthetic-joint-infections/ Wed, 29 Apr 2026 15:03:09 +0000 https://clinicaltrials.eu/trial/study-on-clindamycin-and-rifampicin-for-treating-infections-in-patients-with-obesity-fracture-related-infections-hidradenitis-suppurativa-or-prosthetic-joint-infections/ This clinical trial is focused on studying the treatment of certain infections using the medication clindamycin. The infections being studied include fracture-related infections, hidradenitis suppurativa (a skin condition that causes small, painful lumps under the skin), and prosthetic joint infections. The trial will also examine how the medication rifampicin and a person’s body weight might affect the treatment with clindamycin.

The purpose of the study is to understand how clindamycin is processed in the body and how effective it is when used alone or in combination with rifampicin. Participants will receive either clindamycin by itself or a combination of clindamycin and rifampicin. The study will monitor how the body absorbs and eliminates clindamycin, as well as the overall effectiveness of the treatment in curing the infections.

Participants will take the medication orally, and the study will last for a period of up to 12 weeks. The trial aims to gather information on how well the treatment works and to identify any factors that might influence its success, such as the participant’s weight or the use of additional medications like rifampicin. The ultimate goal is to improve treatment strategies for these infections.

]]> Study on the Effectiveness of AVTX-009 for Treating Moderate to Severe Hidradenitis Suppurativa in Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-avtx-009-for-treating-moderate-to-severe-hidradenitis-suppurativa-in-patients/ Wed, 29 Apr 2026 15:02:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-avtx-009-for-treating-moderate-to-severe-hidradenitis-suppurativa-in-patients/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin. The study will evaluate a treatment called AVTX-009, which is a solution for injection developed by Avalo Therapeutics. The purpose of the study is to assess how effective and safe AVTX-009 is for patients with moderate to severe forms of this condition.

Participants in the study will receive either the AVTX-009 treatment or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased. The treatment will be administered through subcutaneous injections, which means it is injected under the skin. The study will last for a period of 16 weeks, during which the participants’ response to the treatment will be closely monitored.

The main goal is to see if the treatment can reduce the number of painful lumps and improve the overall condition of the skin. Participants will be evaluated on their progress, and any side effects will be recorded to ensure the safety of the treatment. The study will also look at other factors, such as changes in skin pain and the presence of any antibodies against AVTX-009. This research aims to provide valuable information on a potential new treatment option for those suffering from Hidradenitis Suppurativa.

]]> Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-long-term-effects-of-secukinumab-in-patients-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:01:00 +0000 https://clinicaltrials.eu/trial/study-on-long-term-effects-of-secukinumab-in-patients-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying the effects of a medication called secukinumab on a skin condition known as hidradenitis suppurativa. Hidradenitis suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The study aims to understand how effective and safe secukinumab is for people with moderate to severe forms of this condition. Secukinumab is given as a solution for injection under the skin.

The purpose of the study is to compare the long-term effects of continuous versus interrupted treatment with secukinumab. Participants who have already responded well to secukinumab in previous studies will continue to receive the medication, while others will receive a placebo. The study will monitor how long it takes for symptoms to return in those who stop the medication compared to those who continue it. The study will also keep track of any side effects, changes in laboratory test results, and vital signs to ensure the treatment is safe.

Participants in the study will receive injections of secukinumab or a placebo over a period of time, and their progress will be monitored regularly. The study is designed to last until 2026, allowing researchers to gather comprehensive data on the long-term effects of the treatment. This information will help determine the best way to manage hidradenitis suppurativa with secukinumab in the future.

]]> Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-bimekizumab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:00:52 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-bimekizumab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying the long-term effects of a treatment for Hidradenitis Suppurativa, a skin condition that causes painful lumps under the skin, often in areas like the armpits and groin. The treatment being tested is called bimekizumab, which is given as a solution for injection. Bimekizumab is also known by its code name, UCB4940. The purpose of the study is to evaluate the safety of using bimekizumab over an extended period in adults with moderate to severe cases of this condition.

Participants in the study will receive bimekizumab through injections under the skin. The study will monitor participants for any side effects and assess how well the treatment works in managing the symptoms of Hidradenitis Suppurativa. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of bimekizumab. The study will also look at how the treatment affects the quality of life and skin pain experienced by participants.

The study is designed to last for several months, allowing researchers to gather information on the long-term use of bimekizumab. Participants will be regularly checked to ensure their safety and to track any changes in their condition. The results will help determine if bimekizumab is a safe and effective long-term treatment option for people with moderate to severe Hidradenitis Suppurativa.

]]> Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-lutikizumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-in-patients-aged-16-and-older/ Wed, 29 Apr 2026 14:58:14 +0000 https://clinicaltrials.eu/trial/study-on-lutikizumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-in-patients-aged-16-and-older/ This clinical trial focuses on evaluating a treatment for Hidradenitis Suppurativa (HS), a chronic skin condition that causes painful bumps and abscesses in areas where skin rubs together. The study examines the effectiveness and safety of Lutikizumab (also known as ABT-981) compared to placebo in people with moderate to severe forms of the condition.

The treatment involves receiving either Lutikizumab or placebo through subcutaneous injection (an injection under the skin). The medication being tested is a biotechnology product that aims to reduce the signs and symptoms of moderate to severe Hidradenitis Suppurativa. The study will assess how well the treatment works in both adults and adolescents who have had inadequate results with previous treatments.

The study will measure several aspects of the condition, including reduction in the number of inflammatory bumps and draining wounds, improvement in pain levels, and changes in quality of life. The treatment period will last for several months to properly evaluate the medication’s effectiveness. Throughout the study, participants will be closely monitored to ensure their safety and to track their response to the treatment.

]]> Study on the Use of Adipose-Derived Stem Cells for Treating Hidradenitis Suppurativa in Patients with Draining Fistulas https://clinicaltrials.eu/trial/study-on-the-use-of-adipose-derived-stem-cells-for-treating-hidradenitis-suppurativa-in-patients-with-draining-fistulas/ Wed, 29 Apr 2026 14:58:00 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-adipose-derived-stem-cells-for-treating-hidradenitis-suppurativa-in-patients-with-draining-fistulas/ This clinical trial is focused on studying a skin condition called hidradenitis suppurativa. This condition is characterized by painful lumps under the skin, often in areas like the armpits or groin, which can develop into draining fistulas. The trial is testing a new treatment using allogeneic adipose-derived adult mesenchymal stem cells, which are special cells taken from fat tissue and expanded in a lab. These cells are injected directly into the affected areas to see if they can help heal the fistulas.

The purpose of the study is to evaluate the safety and effectiveness of this stem cell treatment. Participants will be randomly assigned to receive either the stem cell treatment or a placebo. The study will monitor participants for any side effects and measure how well the treatment works in closing the fistulas and reducing symptoms over a period of 24 weeks. The trial will also look at changes in symptoms like pain and inflammation, as well as overall quality of life.

Throughout the study, participants will have regular check-ups to assess their progress. The trial aims to provide valuable information on whether this new treatment can offer a safe and effective option for people suffering from hidradenitis suppurativa. The study is expected to continue until 2027, allowing for comprehensive follow-up and analysis of the results.

]]> Study on Amlitelimab for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-amlitelimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 14:56:52 +0000 https://clinicaltrials.eu/trial/study-on-amlitelimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin, often in areas like the armpits and groin. The trial is testing a new treatment called amlitelimab, which is given as a solution for injection under the skin. Amlitelimab is a type of protein designed to help reduce inflammation and improve symptoms in people with moderate to severe forms of this condition.

The purpose of the study is to evaluate how effective and safe amlitelimab is for treating hidradenitis suppurativa. Participants in the study will receive either amlitelimab or a placebo, which looks like the treatment but does not contain the active substance. The study will follow participants over a period of time to observe any changes in their condition and to monitor for any side effects. The main goal is to see if participants experience a reduction in the severity of their symptoms.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. This includes monitoring the number and size of skin lumps, as well as any changes in pain levels and overall quality of life. The study aims to provide valuable information on whether amlitelimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa.

]]> Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ianalumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-in-patients/ Wed, 29 Apr 2026 14:29:32 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ianalumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-in-patients/ This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is characterized by painful lumps under the skin, often in areas like the armpits or groin. The study is looking at patients with moderate to severe forms of this condition. The main goal is to evaluate the effectiveness and safety of different investigational drugs compared to a placebo. One of the investigational drugs being tested is called VAY736, which is also known by its active substance name, ianalumab. This drug is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

Participants in the study will receive either the investigational drug or a placebo. The study is designed to be “blinded,” meaning neither the participants nor the researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of 16 weeks, during which the participants’ response to the treatment will be closely monitored. The primary focus is to see how many patients show a clinical response, which means an improvement in their condition, after the treatment period.

Throughout the study, the safety of the participants will be a top priority. This includes monitoring for any side effects or adverse events, as well as conducting regular physical examinations and checking vital signs. The study aims to provide valuable information on the potential benefits and risks of using VAY736 for treating moderate to severe hidradenitis suppurativa, which could lead to new treatment options for patients with this challenging condition.

]]> Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-povorcitinib-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 14:29:26 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-povorcitinib-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying the long-term safety and effectiveness of a medication called Povorcitinib for individuals with a skin condition known as Hidradenitis Suppurativa. Hidradenitis Suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The study aims to understand how safe Povorcitinib is when used over an extended period.

Participants in the study will take Povorcitinib in the form of a tablet, which is taken orally. The study will last for up to 54 weeks, during which participants will be monitored for any side effects or changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substance. The study will help determine if Povorcitinib is a safe and effective treatment option for managing the symptoms of Hidradenitis Suppurativa.

Throughout the study, researchers will collect information on any adverse events, which are any unwanted effects that occur while taking the medication. They will also assess how well the medication works in reducing the symptoms of Hidradenitis Suppurativa, such as the number of lumps and tunnels under the skin. This information will contribute to understanding the potential benefits and risks of using Povorcitinib for this condition.

]]> Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study https://clinicaltrials.eu/trial/study-on-long-term-use-of-spesolimab-for-patients-with-hidradenitis-suppurativa-who-completed-a-previous-spesolimab-study/ Wed, 29 Apr 2026 14:28:51 +0000 https://clinicaltrials.eu/trial/study-on-long-term-use-of-spesolimab-for-patients-with-hidradenitis-suppurativa-who-completed-a-previous-spesolimab-study/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa (HS). HS is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The trial involves a treatment called Spesolimab, which is a solution for injection. Spesolimab is a type of medication known as a humanized monoclonal antibody, which is designed to target specific proteins in the body that may be involved in causing inflammation.

The purpose of this study is to assess the long-term safety of Spesolimab in people with HS who have already participated in a previous study with this medication. Participants in this trial will receive Spesolimab or a placebo, which is a substance with no active medication, to compare the effects. The study will monitor participants over a period to observe any side effects or changes in their condition.

Throughout the study, participants will receive regular injections of Spesolimab and will be closely monitored by healthcare professionals. The trial aims to provide valuable information on how safe and effective Spesolimab is for long-term use in treating HS. This information could help improve treatment options for people living with this challenging skin condition.

]]> Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-of-eltrekibart-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 14:28:21 +0000 https://clinicaltrials.eu/trial/study-of-eltrekibart-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin, often in areas like the armpits, groin, and under the breasts. The study is specifically looking at adults with moderate to severe forms of this condition. The treatment being tested is a medication called Eltrekibart, which is a type of protein known as a monoclonal antibody. This protein is designed to target and block certain substances in the body that are involved in inflammation, potentially reducing the symptoms of Hidradenitis Suppurativa.

The purpose of the study is to determine if Eltrekibart is more effective than a placebo in improving the condition of participants with moderate to severe Hidradenitis Suppurativa. Participants in the study will receive either Eltrekibart or a placebo through a method called subcutaneous injection, which means the medication is injected under the skin. The study will last for a period of up to 50 weeks, during which participants will be monitored to see if there is an improvement in their symptoms.

Throughout the study, researchers will assess the participants’ response to the treatment by looking for a specific improvement known as the Hidradenitis Suppurativa Clinical Response 50 (HiSCR50). This measure indicates a significant reduction in the number of painful lumps and other symptoms. The study aims to provide valuable information on whether Eltrekibart can be a beneficial treatment option for people suffering from this challenging skin condition.

]]> Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure https://clinicaltrials.eu/trial/study-on-upadacitinib-for-adults-and-adolescents-with-moderate-to-severe-hidradenitis-suppurativa-after-anti-tnf-therapy-failure/ Wed, 29 Apr 2026 14:26:41 +0000 https://clinicaltrials.eu/trial/study-on-upadacitinib-for-adults-and-adolescents-with-moderate-to-severe-hidradenitis-suppurativa-after-anti-tnf-therapy-failure/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin. The trial will evaluate a medication called Upadacitinib, which is taken as a modified-release tablet. The purpose of the study is to assess how effective and safe Upadacitinib is for adults and adolescents who have moderate to severe Hidradenitis Suppurativa and have not responded well to previous treatments known as anti-TNF therapy.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of time, during which participants will take the medication or placebo and attend regular check-ups to monitor their condition and any changes in their symptoms. The main goal is to see if there is a significant reduction in the number of painful lumps and other symptoms associated with Hidradenitis Suppurativa after 16 weeks of treatment.

Throughout the study, participants will be asked to report on their skin condition, including any changes in pain levels and quality of life. The study aims to provide valuable information on whether Upadacitinib can be a beneficial treatment option for those suffering from this challenging skin condition. The trial is expected to continue until 2027, with recruitment starting in late 2023.

]]> Study on Izokibep for Patients with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-izokibep-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ Wed, 29 Apr 2026 14:26:11 +0000 https://clinicaltrials.eu/trial/study-on-izokibep-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is characterized by painful lumps under the skin, often in areas like the armpits and groin. The study is testing a treatment called Izokibep, which is given as an injection under the skin. The purpose of the study is to evaluate how effective and safe Izokibep is for people with moderate to severe forms of this condition.

Participants in the study will be randomly assigned to receive either Izokibep or a placebo, which looks like the treatment but does not contain the active medicine. The study will last for several weeks, during which participants will receive regular injections and attend follow-up visits to monitor their progress and any changes in their condition. The main goal is to see if the treatment helps reduce the symptoms of Hidradenitis Suppurativa by a significant amount by the end of the study period.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study aims to provide valuable information on whether Izokibep can be a beneficial treatment option for those suffering from this challenging skin condition.

]]>